Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Exemestane (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 28 May 2021 Biomarkers information updated
- 18 Oct 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 27 Apr 2013 New trial record